US organizations opposed to the use of the abortion pill RU-486(mifepristone) are boycotting Hoechst Marion Roussel's new antiallergy drug Allegra (fexofenadine), because of the company's links with Roussel Uclaf, RU-486's developer. However, HMR is now divesting all its interests in this product (see page 22).
"There are few ways to defend American women from the imminent invasion of RU-486," according to Kristi Hamrick, director of communications at the Family Research Council, one of the groups organizing the boycott. "Supporting a boycott of a new, popular drug made by a company with ties to the production of RU-486 is one powerful way to say 'Americans won't tolerate deadly drugs.'"
Ms Hamrick says that RU 486 was placed on a fast-track approval process by the Food and Drug Administration even though there was no public demand for it. "Such a fast approval of the abortion drug only benefits the multi-million dollar abortion industry at the expense of the health and safety of women. A drug which takes women into the dark and lonely corners of their homes to kill their babies, risking their own lives in the process, should not be produced or distributed in any country."Other organizations involved in the boycott include the National Right to Life Committee, the Christian Coalition, the Southern Baptist Convention and Concerned Women for America.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze